Evidence map›Paper›PMID 37497711›Full record

ReviewCurrent medicinal chemistry2024

Molecular Mechanisms and Therapeutic Potential of Resolvins in Cancer - Current Status and Perspectives.

Amir Tajbakhsh, Fatemeh Yousefi, Najmeh Farahani, Amir Savardashtaki, Željko Reiner, Tannaz Jamialahmadi, Amirhossein Sahebkar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Amir TajbakhshPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Fatemeh YousefiDepartment of Biological Sciences, Faculty of Genetics, Tarbiat Modares University, Tehran, Iran.
Najmeh FarahaniDepartment of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran.
Amir SavardashtakiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Željko ReinerDepartment of Internal Medicine, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Tannaz JamialahmadiApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amirhossein SahebkarApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRShiraz University of Medical Sciences · IRIsfahan University of Medical Sciences · IRPolish Mother’s Memorial Hospital Research Institute · PLTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resolvins are specialized pro-resolving mediators derived from omega-3 fatty acids that can suppress several cancer-related molecular pathways, including important activation of transcription parameters in the tumor cells and their microenvironment, inflammatory cell infiltration, cytokines as well as chemokines. Recently, an association between resolvins and an important anti-inflammatory process in apoptotic tumor cell clearance (efferocytosis) was shown. The inflammation status or the oncogene activation increases the risk of cancer development

Indexed as

NeoplasmsAnimalsAntineoplastic AgentsDocosahexaenoic AcidsHumansInflammationTumor MicroenvironmentAntineoplastic AgentsDocosahexaenoic Acidscancer therapychemotherapy.Endogenous modulatorpainphagocytosisresolutiontumor progression

Identifiers

PMID37497711
OpenAlexW4385294452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.